raloxifene hydrochloride has been researched along with fibrinogen in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (91.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, PW; Cox, DA; Dean, RA; Paul, S; Tracy, RP; Walsh, BW; Wild, RA | 1 |
| Arndt, T; Bonnar, J; Creatsas, G; Depypere, H; Erenus, M; Nickelsen, T; Quail, D; Rechberger, T | 1 |
| Blackwell, T; Gilchrist, N; March, R; Shand, B | 1 |
| Celermajer, DS; Griffiths, KA; Harmer, JA; Sader, MA; Skilton, MR | 1 |
| Baber, R; Davis, SR; Eden, J; Ekangaki, A; O'Neill, SM; Stocks, JM; Wolthers, T | 1 |
| Arakil-Aghajanian, A; Blasbichler, M; Sinzinger, H | 1 |
| Creatsas, G; Depypere, H; Liu-Léage, S; Marin, F; Neven, P; Nickelsen, T; Pavo, I; Quail, D; Rechberger, T; Schmitt, H | 1 |
| Azevedo, GD; Baggio, MS; Franco, RF; Maranhão, TM; Sá, MF | 1 |
| Chow, C; Danforth, D; Eng-Wong, J; Gantz, S; Liewehr, D; Liu, ET; Reynolds, JC; Venzon, D; Zujewski, J | 1 |
| Engin-Ustün, Y; Kafkasli, A; Meydanli, MM; Ustün, Y | 1 |
| Fujimura, A; Hasegawa, G; Kaneda, T; Maeda, A; Tsuruoka, S | 1 |
| Gao, H; Xi, S; Xu, L | 1 |
1 review(s) available for raloxifene hydrochloride and fibrinogen
| Article | Year |
|---|---|
Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.
Topics: Bone Remodeling; Drug Combinations; Endometrium; Estradiol; Female; Fibrinogen; Humans; Lipids; Middle Aged; Multicenter Studies as Topic; Postmenopause; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators | 2005 |
8 trial(s) available for raloxifene hydrochloride and fibrinogen
| Article | Year |
|---|---|
The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.
Topics: Aged; C-Reactive Protein; Double-Blind Method; Estrogen Replacement Therapy; Female; Fibrinogen; Homocysteine; Humans; Lipids; Middle Aged; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risk Factors | 2000 |
Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Estradiol; Estrogen Replacement Therapy; Europe; Female; Fibrinogen; Humans; Lipoproteins; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triglycerides | 2001 |
The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial.
Topics: Aged; Blood Viscosity; Estrogen Antagonists; Female; Fibrinogen; Hemorheology; Humans; Middle Aged; Osteoporosis; Placebos; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stress, Mechanical; Treatment Outcome | 2002 |
Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease.
Topics: Aged; Biomarkers; Coronary Artery Disease; Coronary Vessels; Cross-Over Studies; Double-Blind Method; Endothelin-1; Endothelium, Vascular; Female; Fibrinogen; Humans; Lipoproteins; Middle Aged; Postmenopause; Prospective Studies; Prostaglandins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vasodilation | 2003 |
Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
Topics: Administration, Cutaneous; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Estradiol; Female; Fibrinogen; Humans; Lipids; Middle Aged; Pilot Projects; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Procoagulant state after raloxifene therapy in postmenopausal women.
Topics: Blood Coagulation; Blood Coagulation Factors; Female; Fibrinogen; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Postmenopause; Prospective Studies; Protein C; Protein Precursors; Prothrombin; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thrombosis | 2005 |
Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer.
Topics: Adult; Bone Density; Breast Neoplasms; Female; Fibrinogen; Humans; Lipids; Middle Aged; Premenopause; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2006 |
Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.
Topics: Administration, Intranasal; Double-Blind Method; Estradiol; Estrogen Replacement Therapy; Female; Fibrinogen; Humans; Hypercholesterolemia; Lipids; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2006 |
3 other study(ies) available for raloxifene hydrochloride and fibrinogen
| Article | Year |
|---|---|
Raloxifene does not prevent fibrinogen oxidation in vitro.
Topics: Antioxidants; Fibrinogen; Iron; Oxidation-Reduction; Raloxifene Hydrochloride | 2005 |
Dosing time-dependent effect of raloxifene on plasma fibrinogen concentration in ovariectomized rats.
Topics: Animals; Body Weight; Calcium; Circadian Rhythm; Female; Fibrinogen; Light; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |
[Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats].
Topics: Animals; Antithrombin III; Disease Models, Animal; Estrogens, Conjugated (USP); Female; Fibrinogen; Fibrinolysis; Ovariectomy; Plasminogen Activator Inhibitor 1; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Sprague-Dawley; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis | 2013 |